The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.
L. Bordeleau
No relevant relationships to disclose
G. Dagenais
No relevant relationships to disclose
N. Yakubovich
No relevant relationships to disclose
S. Yusuf
Consultant or Advisory Role - Novo Nordisk; Sanofi
Honoraria - Novo Nordisk; Sanofi
Research Funding - Novo Nordisk; Sanofi
J. Probstfield
Research Funding - Sanofi
M. Riddle
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
L. Ryden
No relevant relationships to disclose
L. Xu
No relevant relationships to disclose
J. Bosch
Consultant or Advisory Role - Novo Nordisk; Sanofi
Honoraria - Novo Nordisk; Sanofi
Research Funding - Novo Nordisk; Sanofi
H. Gerstein
Consultant or Advisory Role - Novo Nordisk; Sanofi
Honoraria - Novo Nordisk; Sanofi
Research Funding - Novo Nordisk; Sanofi